Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

First Helium: a Canadian company exploring and developing two premier helium projects

When you think of Alberta, Helium companies may not be top of mind. But look no further, First Helium has identified many follow-up drill locations and acquired a well operating infrastructure system which will help expand future exploration programs. Consisting of t...

PDAC 2021 Day 4: Predictions of the Markets, Commodities, and Resources

PDAC 2021 – the preeminent event for the world’s mineral exploration and mining industry, and first-ever to be held virtually – wraps up today with capital markets’ proverbial 'fortune tellers' looking into their crystal balls to predict what...

New Data Could Drive Use of Pancreatic Cancer Early Detection Test

The recent results and their implications are provided in an H.C. Wainwright & Co. report. In an Oct. 25 research note, H.C. Wainwright & Co. analyst Yi Chen reported that newly compiled data support the clinical utility of Interpace Diagnostics Group Inc.'s (IDXG:NA...

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant

Neurotrope's shares traded higher today after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm has also been awarded a $2.7 million grant from the National Institutes of Health t...

Have the Stock Bulls Really Sealed the Short-Term Crack in the Dam?

Stocks again made a new intraday 2020 high yesterday, but the bulls were stopped just a point shy of the 3395 mark. Has yesterday’s increase invalidated our reasons to be cautious and take profits off the table? In other words, can we expect the bulls to push t...

Can the Efforts to Turn S&P 500 Around Really Stick?

While Friday’s session turned out kind of undecided, it was still a down session with the bears bringing home the bacon. Can the same conclusion be reached when examining the weekly chart? And what about other valuable clues as to the upcoming S&P 500 move? ...

Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data

Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease. Clinical-stage biotechnology company Cassava Sciences Inc. (SAVA:NASDAQ) , which focuses on neurodegenerative di...

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...

Biotech Identifies Antibody with 100% SARS-CoV-2 Inhibition

The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report. In a May 26 research note, Dawson James analyst Jason Kolbert reported that Sorrento Therape...
1 2 3